RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: Role in chemotherapy sensitivity in acute megakaryocytic leukemia

Blood

Volumn 114, Issue 13, 2009, Pages 2744-2752

  Edwards, Holly ^a   Xie, Chengzhi ^a,b   LaFiura, Katherine M ^a   Dombkowski, Alan A ^c   Buck, Steven A ^d   Boerner, Julie L ^a   Taub, Jeffrey W ^a,d   Matherly, Larry H ^a   Ge, Yubin ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c WAYNE STATE UNIVERSITY   (United States)

^d CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYTARABINE; PHOSPHATIDYLINOSITOL 3 KINASE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RUNX1; ONCOPROTEIN; PIK3CD PROTEIN, HUMAN; RUNX1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DOWN SYNDROME; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME REGULATION; GROUPS BY AGE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPORTER GENE; TREATMENT RESPONSE; CELL STRAIN K 562; COMPARATIVE STUDY; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CHILD; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTARABINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEIN V-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 70350506780     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-179812     Document Type: Article

References (52)

1. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004;104(12):3679-3687. (Pubitemid 39564445)
2. Lutterbach B, Hiebert SW. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene. 2000;245(2):223-235. (Pubitemid 30136427)
3. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23(24):4255-4262.
4. Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest. 2000;18(8):768-780. (Pubitemid 30943767)
5. Okuda T, van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84(2):321-330. (Pubitemid 26042836)
6. Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996;93(8):3444-3449. (Pubitemid 26125639)
7. Sasaki K, Yagi H, Bronson RT, et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc Natl Acad Sci U S A. 1996;93(22):12359-12363. (Pubitemid 26367148)
8. Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 1996;87(4):697-708. (Pubitemid 26386943)
9. Song WJ, Sullivan MG, Legare RD, et al. Haplo-insufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166-175.
10. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99(4):1364-1372. (Pubitemid 34547093)
11. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study-POG 8821. Blood. 1999;94(11):3707-3716.
12. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293(2):203-211. (Pubitemid 40095871)
13. Schnittger S, Kohl TM, Haferlach T, et al. KITD816 mutations in AML1-ETO positive AML are associated with impaired event-free and overall survival. Blood. 2006;107(5):1791-1799. (Pubitemid 43289355)
14. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463-3468.
15. Shimada A, Taki T, Tabuchi K, et al. KIT mutations, and FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood. 2006;107(5):1806-1809. (Pubitemid 43289357)
16. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-3911. (Pubitemid 46630738)
17. Loh ML, Goldwasser MA, Silverman LB, et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 2006;107(11):4508-4513.
18. Robinson HM, Broadfield ZJ, Cheung KL, et al. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia. 2003;17(11):2249-2250. (Pubitemid 37428400)
19. Bourquin JP, Subramanian A, Langebrake C, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2006;103(9):3339-3344. (Pubitemid 43346471)
20. Ravindranath Y, Abella E, Krischer J, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 1992;80(9):2210-2214.
21. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med. 1996;334(22):1428-1434. (Pubitemid 26157438)
22. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998;91(2):608-615. (Pubitemid 28053385)
23. Gamis AS, Woods WG, Alonzo TA, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol. 2003;21(18):3415-3422.
24. Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005;19(8):1355-1360. (Pubitemid 41136328)
25. Zipursky A, Thorner P, De Harven E, et al. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res. 1994;18(3):163-171. (Pubitemid 24127571)
26. Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia. 2000;14(5):786-791. (Pubitemid 30235053)
27. Ge Y, Dombkowski AA, LaFiura KM, et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood. 2006;107(4):1570-1581. (Pubitemid 43242396)
28. Ge Y, LaFiura KM, Dombkowski AA, et al. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia. 2008;22(3):521-529.
29. Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268(5218):1766-1769.
30. Ding BC, Whetstine JR, Witt TL, et al. Repression of human reduced folate carrier gene expression by wild type p53. J Biol Chem. 2001;276(12):8713-8719. (Pubitemid 37385438)
31. LaFiura KM, Edwards H, Taub JW, et al. Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group. Oncogene. 2008;27(36):4933-4942.
32. Ge Y, Stout ML, Tatman DA, et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst. 2005;97(3):226-231. (Pubitemid 40277373)
33. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681.
34. Ge Y, Jensen TL, Matherly LH, et al. Transcriptional regulation of the cystathionine-β-synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Blood. 2003;101(4):1551-1557. (Pubitemid 36182533)
35. Weng L, Dai H, Zhan Y, et al. Rosetta error model for gene expression analysis. Bioinformatics. 2006;22(9):1111-1121.
36. Martelli AM, Nyakern M, Tabellini G, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia. 2006;20(6):911-928. (Pubitemid 43797279)
37. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood. 2005;106(3):1063-1066. (Pubitemid 41076455)
38. Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist. 2007;12(3):341-355. (Pubitemid 46562369)
39. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukemia. Lancet. 2008;371(9617):1030-1043.
40. Rubnitz JE, Razzouk BI, Lensing S, et al. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer. 2007;109(1):157-163. (Pubitemid 46120203)
41. Oki Y, Kantarjian HM, Zhou X, et al. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006;107(3):880-884. (Pubitemid 43156282)
42. Pagano L, Pulsoni A, Vignetti M, et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia. 2002;16(9):1622-1626. (Pubitemid 35050090)
43. Paredes-Aguilera R, Romero-Guzman L, Lopez-Santiago N, et al. Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children. Am J Hematol. 2003;73(2):71-80. (Pubitemid 36581923)
44. Reinhard D, Diekamp S, Langebrake C, et al. Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Leukemia. 2005;19(8):1495-1496. (Pubitemid 41136350)
45. Athale UH, Razzouk BI, Raimondi SC, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood. 2001;97(12):3727-3732.
46. Hitzler JK. Acute megakaryocytic leukemia in Down syndrome. Pediatr Blood Cancer. 2007;49(7 suppl):1066-1069. (Pubitemid 350035125)
47. Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood. 2000;96(7):2405-2411. (Pubitemid 30745262)
48. Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002;99(1):245-251.
49. Frost BM, Gustafsson G, Larsson R, et al. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? Leukemia. 2000;14(5):943-944. (Pubitemid 30235076)
50. Klampfer L, Zhang J, Zelenetz AO, et al. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci U S A. 1996;93(24):14059- 14064. (Pubitemid 26424245)
51. Doepfner KT, Boller D, Arcaro A. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol. 2007;63(3):215-230. (Pubitemid 47126864)
52. Malinge S, Ragu C, Della-Valle V, et al. Activating mutations in human acute megakaryocytic leukemia. Blood. 2008;112(10):4220-4226.